These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35876628)

  • 1. Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study.
    Luo L; Shen R; Arora A; Orlow I; Busam KJ; Lezcano C; Lee TK; Hernando E; Gorlov I; Amos C; Ernstoff MS; Seshan VE; Cust AE; Wilmott J; Scolyer RA; Mann G; Nagore E; Funchain P; Ko J; Ngo P; Edmiston SN; Conway K; Googe PB; Ollila D; Lee JE; Fang S; Rees JR; Thompson CL; Gerstenblith M; Bosenberg M; Gould Rothberg B; Osman I; Saenger Y; Reynolds AZ; Schwartz M; Boyce T; Holmen S; Brunsgaard E; Bogner P; Kuan PF; Wiggins C; Thomas NE; Begg CB; Berwick M;
    Pigment Cell Melanoma Res; 2022 Nov; 35(6):605-612. PubMed ID: 35876628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
    Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
    Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.
    Bezić J; Tomić I; Pavić M
    Acta Dermatovenerol Croat; 2024 Mar; 32(1):75-76. PubMed ID: 38946192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathway Alterations in Stage II/III Primary Melanoma.
    Kostrzewa CE; Luo L; Arora A; Seshan VE; Ernstoff MS; Edmiston SN; Conway K; Gorlov I; Busam K; Orlow I; Hernando-Monge E; Thomas NE; Berwick M; Begg CB; Shen R;
    JCO Precis Oncol; 2023 Mar; 7():e2200439. PubMed ID: 36926987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
    Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
    Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.
    Jansen P; Galetzka W; Lodde GC; Standl F; Zaremba A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Placke JM; Landsberg J; Möller I; Sucker A; Paschen A; Hadaschik E; Zimmer L; Livingstone E; Schadendorf D; Ugurel S; Stang A; Griewank KG
    Eur J Cancer; 2024 Sep; 208():114208. PubMed ID: 39018633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
    Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
    Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
    Larsen AC
    Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spitz melanoma is a distinct subset of spitzoid melanoma.
    Raghavan SS; Peternel S; Mully TW; North JP; Pincus LB; LeBoit PE; McCalmont TH; Bastian BC; Yeh I
    Mod Pathol; 2020 Jun; 33(6):1122-1134. PubMed ID: 31900433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
    Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
    Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients.
    Lally SE; Milman T; Orloff M; Dalvin LA; Eberhart CG; Heaphy CM; Rodriguez FJ; Lin CC; Dockery PW; Shields JA; Shields CL
    Ophthalmology; 2022 Jun; 129(6):679-693. PubMed ID: 35085662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site.
    Bauer J; Büttner P; Murali R; Okamoto I; Kolaitis NA; Landi MT; Scolyer RA; Bastian BC
    Pigment Cell Melanoma Res; 2011 Apr; 24(2):345-51. PubMed ID: 21324100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical correlates of NRAS and BRAF mutations in primary human melanoma.
    Ellerhorst JA; Greene VR; Ekmekcioglu S; Warneke CL; Johnson MM; Cooke CP; Wang LE; Prieto VG; Gershenwald JE; Wei Q; Grimm EA
    Clin Cancer Res; 2011 Jan; 17(2):229-35. PubMed ID: 20975100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR.
    Dobre EG; Nichita L; Popp C; Zurac S; Neagu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
    Chang GA; Wiggins JM; Corless BC; Syeda MM; Tadepalli JS; Blake S; Fleming N; Darvishian F; Pavlick A; Berman R; Shapiro R; Shao Y; Karlin-Neumann G; Spittle C; Osman I; Polsky D
    J Invest Dermatol; 2020 Aug; 140(8):1609-1618.e7. PubMed ID: 32087194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
    Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
    Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
    J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.